A Phase 4 interventional study of Adalimumab trough concentration and Usual care in Rheumatoid Arthritis, sponsored by Reade Rheumatology Research Institute. Active, not recruiting at 2 sites in Netherlands. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by Reade Rheumatology Research Institute · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 154 studies in Arthritis, Rheumatoid with a site in Netherlands — 17 open to participants now, 26 under way, 1 of them phase 3. Arthritis, Rheumatoid · Netherlands.
Among the 154 studies in Arthritis, Rheumatoid with a site in Netherlands, this one is the 79th largest by enrollment of the 130 interventional ones that give a count, is one of 7 that started in 2020, is one of 23 in phase 4, reaches primary completion later than 2 of the 25 other live ones, and was the 130th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →17 of the 154 studies in Arthritis, Rheumatoid with a site in Netherlands are open now. Recruiting first, the newest first:
Sint Maartenskliniek · Sites in Netherlands
Ages 18+
Sint Maartenskliniek · Sites in Netherlands
Ages 16+
AstraZeneca · Sites in Netherlands, United States, Canada and 7 more countries
Ages 18–70
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Galvani Bioelectronics · Sites in Netherlands, United Kingdom
Ages 22–75
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
154 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 41 · Phase 3 40 · Phase 4 23
First in 2000; this study’s year is marked. 7 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is below the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 150 across the 130 interventional studies, 435 across the 24 observational. Of the 122 that completed or were terminated, 76 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 154 have an industry lead sponsor. The 10 most frequent:
Reade Rheumatology Research Institute is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Reade Rheumatology Research Institute has 4 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
4 of the studies in Arthritis, Rheumatoid with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02337244Zimmer, GmbHZimmer POLAR Persona - TKA (EMEA Study) | 2026-12 |
| NCT06046950Sint MaartenskliniekTrEatment Targets in Rheumatoid Arthritis: TETRA-study | 2027-02 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT05003310Galvani BioelectronicsConsideRAte Study - Splenic Stimulation for RA | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 154 studies in Arthritis, Rheumatoid with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A potential application of therapeutic drug monitoring is to predict efficacy after switch to another biological in the case of inefficacy of the previous TNF-inhibitor (TNFi) in rheumatoid arthritis (RA) patients. It has been shown that when antidrug antibodies against adalimumab are detected (resulting in lower drug serum concentrations) in patients failing adalimumab, a normal response to a next TNF blocker can be anticipated. However, when clinical response is unsatisfactory and no antidrug antibodies against the first TNFi are detected (generally drug levels are adequate in this case), this predicts a lower response to a next TNFi. This means drug resistant failure in the former, compared to class resistant failure in latter category of patients. The current RA treatment strategy after failure of the first TNF-inhibitor is to start either a second TNFi or a non-TNFi. However, by channelling patients with sufficient adalimumab concentration to a non-TNFi will provide higher chance of disease control. Patients with very low or undetectable drug levels have an equal or potential higher chance of disease control with a drug of the same class (i.e. another TNFi).
Over the last decades biopharmaceuticals such as agents against tumor necrosis factor (TNF), are frequently prescribed to optimize rheumatoid arthritis treatment. Although TNFi such as adalimumab, etanercept and infliximab, have improved the treatment of rheumatoid arthritis, a proportion of patients discontinue the treatment because of inefficacy or intolerance.
Where TNFi have failed, mainly two treatment approaches are available: switch to another TNFi or to a biological with a different mode of action (notably rituximab, abatacept or tocilizumab) or to a target synthetic DMARDs. The EULAR recommendation for the management of rheumatoid arthritis advocate that any biologic agent including a subsequent TNFi can be used with equal chance for effect in case of non-response to a previous TNFi. This recommendation is based on three randomized controlled trails, but it should be noted that systematic reviews also including non-randomized controlled studies sometimes concluded that non-TNFi are more effective after TNFi failure than a second TNFi.
Of note, currently there are no strong predictors available for response to bDMARDS in RA. This study focuses on non-response after adalimumab, as this is the most prescribed TNFi worldwide.
Although it seems that indeed on a group level response to a non-TNFi is comparable to a second TNFi after the first TNFi has failed, using therapeutic drug monitoring could identify subgroups of patient who would benefit more from either a non-TNFi or a TNF-i as next treatment. The underlying pathophysiological mechanisms for this hypothesis are explored in this study.
Nonresponse on adalimumab in RA can have different causes. Firstly, the patient might not be sensitive to TNF blockade at all, or the patient develops this trait later on (primary nonresponse or secondary nonresponse). In these patients, switching to a non-TNFi might conceptually be superior to starting a second TNFi. However, in other patients nonresponse (either primary or secondary) might be caused by inefficient drug concentration because of development of antidrug antibodies against adalimumab. In these patients a TNFi might be just as effective as a non-TNFi, as these patients have drug- but not class failure. Thus, testing of adalimumab levels might be helpful in channelling patients to their most optimal treatment.
Above mentioned hypothesis has been tested in three studies (5) of which one concerned adalimumab in RA. This study showed that response to a second TNFi was indeed higher in patients with antidrug antibodies (ADA) and low adalimumab levels, and lower in patients with adequate adalimumab levels. However, a diagnostic study comparing a serum concentration guided versus usual care switching strategy has not yet been performed.
In this multi-centre, double blinded randomized controlled trial it will be evaluated whether clinical outcome after switching to a subsequent biological treatment is superior with a switching strategy using adalimumab concentration compared to usual care switching strategy.
Patients with rheumatoid arthritis starting another bDMARD (biologic disease modifying antirheumatic drugs) after adalimumab failure (defined as DAS28-CRP >2.9) are randomly assigned to usual care (with randomized switch to etanercept or to a non-TNFi) or 'drug concentration' guided switch.
Data regarding disease status, functioning, adverse events and use of co-medication/rescue medication will be collected during this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Based on a secondary randomization schedule patients are treated with etanercept or a non-TNFi (abatacept, rituximab, tocilizumab, or sarilumab)
Other: Usual care
Patients with a concentration \<1.0 mg/L switch to etanercept and patients with a concentration ≥ 1.0 start a non-TNFi (abatacept, rituximab, tocilizumab, or sarilumab)
Diagnostic Test: Adalimumab trough concentration
In the 'drug concentration guided' group, switching to subsequent biological is based on adalimumab trough concentration
In the usual care group, switch to subsequent biological is based on secondary randomisation
mean time weighted DAS28-CRP
difference in mean time weighted DAS28-CRP between the two groups
Time frame: 24 weeks
Good or moderate response according the EULAR response criteria
Percentage of patients with good or moderate response according the EULAR response criteria
Time frame: 12 en 24 weeks
Minimal disease activity (DAS28-CRP<2.9)
Percentage of patients with minimal disease activity (DAS28-CRP\<2.9)
Time frame: 24 weeks
Non-responders
Percentage of patients with no response according to EULAR response criteria
Time frame: 24 weeks
Number of adverse events
The number of adverse events
Time frame: 24 weeks
Severity of adverse events
Severity of adverse events
Time frame: 24 weeks
Cumulative dose co-medication
Cumulative dose of co-medication
Time frame: 24 weeks
Times co-medication is used
Number of times co-medication is used
Time frame: 24 weeks
Cumulative dose of rescue medication
Cumulative dose of rescue medication
Time frame: 24 weeks
Times rescue medication is used
Number of times co-medication is used
Time frame: 24 weeks
Plan to share: Yes — To avoid duplication of research, the gathered data will be shared once all desirable data analysis have been performed and the results are published
Supporting information: Study protocol, Statistical analysis plan
Time frame: Six months after the study is published the data will be shared
Access criteria: Researchers with demonstrable interest in autoimmunity, biologicals, or therapeutic drug monitoring (TDM) can contact the investigators of the trial if they are interested in gaining access to the data. Depending on their research objectives the data will be shared
Started Jul 2020 (actual). Primary completion is estimated for May 2024, 45 months after the start.
Of 79 non-industry phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 92. This study's planned 45 months is close to that.
Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Reade Rheumatology Research Institute